MIDOD
Effect of Adding Midazolam to Dual Prophylaxis of Dexamethasone and Ondansetron for Preventing Postoperative Nausea and Vomiting (PONV)
Sponsor study identifier
interventional
300
1 country
1
Study Start
December 2, 2025
Actual (reported)Primary Completion
June 1, 2026
Actual (reported)Study Completion
June 1, 2026
Actual (reported)This randomized controlled trial was conducted to evaluate the efficacy of adding midazolam to standard dual antiemetic prophylaxis with dexamethasone and ondansetron for the prevention of postoperative nausea and vomiting (PONV) in patients undergoing elective gynecological laparoscopic surgery. PONV is a common postoperative complication that significantly affects patient comfort, delays recovery, and may prolong hospital stay. Despite the use of established dual prophylaxis with dexamethasone and ondansetron, a considerable proportion of patients continue to experience nausea and vomiting, particularly in high-risk populations such as females undergoing laparoscopic gynecological procedures. Midazolam, a short-acting benzodiazepine, has shown potential antiemetic properties in recent studies, but its role as an adjunct in standard prophylactic regimens remains controversial. The study was conducted in the Department of Anesthesiology at Hameed Latif Hospital, Lahore, over a period of six months from 02-12-2025 to 01-06-2026. A total of 300 eligible patients aged 19-65 years with ASA physical status I-II undergoing elective gynecological laparoscopic surgery were enrolled after obtaining informed written consent. Patients with significant comorbidities, contraindications to study drugs, or factors influencing PONV assessment were excluded. Participants were randomly allocated into two equal groups (150 patients each) using a computer-generated randomization sequence with allocation concealment through sealed opaque envelopes. Group A received standard prophylaxis with dexamethasone and ondansetron along with intravenous normal saline. Group B received the same dual prophylaxis in addition to intravenous midazolam at a dose of 0.05 mg/kg administered after preoxygenation and before induction of anesthesia. Blinding was maintained by using identical syringes, and drug administration was performed by an anesthesiologist not involved in outcome assessment. All patients received standardized general anesthesia, including induction with propofol, fentanyl, and atracurium, and maintenance with isoflurane in oxygen/air mixture. Neuromuscular blockade was reversed appropriately at the end of the procedure. Postoperative care and analgesia were standardized for all patients. The primary outcome was the efficacy of antiemetic prophylaxis, defined as a postoperative nausea and vomiting visual numeric rating scale (VNRS) score of less than 4. PONV was assessed at 0 (post-anesthesia care unit), 6, 12, and 24 hours postoperatively. Secondary outcomes included comparison of VNRS scores over time and requirement of rescue antiemetics. Rescue antiemetics were administered as per protocol when clinically indicated. Data were analyzed using SPSS version 26.0. Continuous variables were expressed as mean ± standard deviation, and categorical variables as frequency and percentages. The Shapiro-Wilk test was used to assess normality. Group comparisons were performed using Chi-square or Fisher's exact test, with a p-value ≤0.05 considered statistically significant. Stratified analysis was also conducted for age, body mass index, ASA status, and type of surgical procedure.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 1, 2026
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2, 2025
Actual (reported)June 1, 2026
Actual (reported)June 1, 2026
Actual (reported)June 13, 2026
Actual (reported)June 25, 2026
Actual (reported)Efficacy of antiemetic prophylaxis in prevention of postoperative nausea and vomiting (PONV)
The primary outcome was the efficacy of antiemetic prophylaxis, defined as the proportion of patients achieving a visual numeric rating scale (VNRS) score of less than 4 for postoperative nausea at 6, 12, and 24 hours after surgery. VNRS ranged from 0 (no nausea) to 10 (worst possible nausea), with scores ≥4 considered clinically significant PONV. Assessments were performed at predefined time intervals in the post-anesthesia care unit, and at 6, 12, and 24 hours postoperatively. The comparison was made between patients receiving standard dual prophylaxis (dexamethasone and ondansetron with placebo) and those receiving additional intravenous midazolam. The outcome measured the overall effectiveness of the intervention in reducing clinically significant postoperative nausea and vomiting.
6 hours, 12 hours, and 24 hours postoperatively
Participants in this arm received standard antiemetic prophylaxis consisting of intravenous dexamethasone 0.1 mg/kg administered after induction of anesthesia and ondansetron 0.1 mg/kg administered at the end of surgery. In addition, an equivalent volume of normal saline (placebo) was administered intravenously after preoxygenation prior to induction. All patients underwent standardized general anesthesia. This arm served as the control group to compare the efficacy of dual prophylaxis alone in preventing postoperative nausea and vomiting (PONV).
Participants in this arm received intravenous midazolam 0.05 mg/kg administered after preoxygenation and before induction of anesthesia, in addition to standard dual antiemetic prophylaxis consisting of dexamethasone 0.1 mg/kg after induction and ondansetron 0.1 mg/kg at the end of surgery. All patients underwent standardized general anesthesia. This arm evaluated the added effect of midazolam as an adjunct to dual prophylaxis for prevention of postoperative nausea and vomiting (PONV) in patients undergoing gynecological laparoscopic surgery.
Placebo (0.9% normal saline) with dexamethasone and ondansetron for PONV prevention
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Midazolam 0.05 mg/kg IV as adjunct to dexamethasone and ondansetron for PONV prevention
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordDepartment of Anaesthesiology
Lahore, Punjab Province, 54590, Pakistan
1. Kanya K, Tayung RP, Das KK. An observational study on the incidence and risk factors of postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic surgeries. Eur J Cardiovasc Med. 2025;15(3):510-2. doi:10.5083/ejcm/25-05-91. 2. Zhao X, Liao W, Chen C, Zheng Y, Li L, Chang Q, et al. Postoperative nausea and vomiting: translating pathophysiological mechanisms into clinical management. Perioper Med. 2025;14(1):140. doi: 10.1186/s13741-025-00626-5. 3. Timerga S, Befkadu A. Prevalence and associated factors of postoperative nausea and vomiting among adult patients undergoing elective surgery. Ann Med Surg. 2024;86(3):1304-8. doi:10.1097/MS9.0000000000001678. 4. Mieszczański P, Jurczak M, Cylke R, Ziemiański P, Trzebicki J. Evidence-based perioperative prevention of postoperative nausea and vomiting (PONV) in Patients undergoing laparoscopic bariatric surgery: a scoping review. J Clin Med. 2025;14(19):6901. 5. Hailu S, Mekonen S, Shiferaw A. Prevention and management of postoperative nausea and vomiting after cesarean section: a systematic literature review. Ann Med Surg. 2022;75(1):103433. doi:10.1016/j.amsu.2022.103433. 6. Schlesinger T, Meybohm P, Kranke P. Postoperative nausea and vomiting: risk factors, prediction tools, and algorithms. Curr Opin Anesthesiol. 2023;36(1):117-23. doi: 10.1097/ACO.0000000000001220. 7. Lin C, Li J, Wu Q, Luo T, Zheng Z. Postoperative nausea and vomiting in female patients undergoing laparoscopic gastrointestinal surgery with double prophylactic therapy. Surg J. 2024;10(02):e25-30. doi: 10.1055/s-0044-1787305. 8. Hu B, Zhou H, Zou X, Shi J, Li X, Tan L. A comparison of dexmedetomidine and midazolam for the prevention of postoperative nausea and vomiting caused by hemabate in cesarean delivery: a randomized controlled trial. Drug Design Develop Ther. 2020;28:2127-33. doi:10.2147/DDDT.S251525. 9. Singh MP, Gupta A, Bhardwaj S. Continuum-based postoperative nausea and vomiting prophylaxis protocol: development and real-w
300 participants (actual enrollment reported by the registry).
Contact the study team to confirm eligibility.
First Submitted
June 13, 2026
First Posted
June 25, 2026
Study Start
December 2, 2025
Actual (reported)Primary Completion
June 1, 2026
Actual (reported)Study Completion
June 1, 2026
Actual (reported)Last Updated
June 25, 2026
Record last verified: 2026-06
Individual participant data (IPD) will not be shared due to institutional and ethical restrictions governing patient confidentiality and data protection. The dataset contains sensitive perioperative clinical information collected from surgical patients, and there is no formal data-sharing agreement or approved repository for external access. Additionally, the informed consent obtained from participants did not include provisions for public data sharing. The data will remain securely stored within the Department of Anesthesiology, Hameed Latif Hospital, Lahore, and will be used solely for the purposes of statistical analysis and publication of study findings. Access to raw data may be granted only upon reasonable request from regulatory authorities or the institutional ethics committee.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: